Perma-Fix (PESI) Q3 2026 Earnings Call Transcript

Perma-Fix reported Q3 revenue of $17.9 million, up 3% year over year and 39% sequentially, but its net loss widened to $3.5 million from $1.8 million and its EBITDA loss to $3.1 million from $1.5 million. Treatment margins turned negative amid lower volumes, processing delays and $1.1 million in higher fixed costs; the Treatment backlog rose 65% from year-end to $19.6 million, while Services revenue grew 46% to $6.3 million and returned to operating income. Management cited ongoing going-concern doubts and possible regulatory delays to Hanford East-area receipts, while expecting growth from DFLAW, price increases and expanded treatment capacity.

Analysis

PESI’s setup is an execution-and-liquidity test, not yet a clean backlog-to-earnings inflection. Treatment has high fixed-cost exposure: delayed receipts or weak waste mix can erase the benefit of higher pricing, while reliable throughput could produce meaningful operating leverage. The Services segment’s improvement is encouraging, but its current scale does not by itself resolve consolidated cash burn. Treat the Hanford IDIQ ceiling as access to compete for task orders—not contracted revenue; shared awards, permitting, DOE shipment schedules, and third-party disposal logistics determine conversion. The East-area review is a near-term timing risk, while DFLAW’s operating-contractor transition and eventual AMPS capacity are multi-year volume options, not assured receipts. PFAS regulation and Gen 2.0 commissioning offer a separate 2027 catalyst, but capacity claims need commercial operating proof. The asymmetry is real: successful utilization and price realization could improve margins, but continued cash use may force financing before those opportunities mature. Immediate reaction may favor backlog and Hanford optionality; over 1–3 months, task orders, shipment cadence, and treatment margins matter more. Over 6–18 months, cash generation and permit/commissioning milestones determine whether the growth story can fund itself. Contrarian point: the headline backlog increase may overstate near-term value if processing delays persist; conversely, the going-concern language is backward-looking accounting evidence, but cannot be dismissed while operating cash flow remains negative.

Key Decisions for Investors

• Keep PESI on a watchlist rather than buy the backlog narrative now. Reassess after evidence that new pricing is lifting Treatment gross margin and delayed streams are being processed at sustained volume; verify next-quarter segment margins, receipts versus revenue, and operating cash flow.
• Do not capitalize the shared IDIQ ceiling as revenue. Track actual task orders, East-area permit responses, and DFLAW shipment cadence separately; a further multi-month permit delay or continued mismatch between receipts and processing would weaken the thesis.
• For existing exposure, size as a speculative, financing-sensitive position and avoid adding until cash burn moderates. The company reported $10.8 million of operating cash use over nine months; another equity raise or worsening liquidity would be a key downside catalyst despite management’s stated view that one is not currently needed.
• Upgrade the outlook only if treatment utilization and mix improve, Services remains profitable, and cash flow turns toward breakeven without relying on new equity. Failure to show that progression over the next few quarters would falsify the self-funded growth case; Gen 2.0 commissioning and PFAS demand remain watch items until operational results are disclosed.